Literature DB >> 25695618

TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives.

Martina Chittani1, Roberta Zaninello, Chiara Lanzani, Francesca Frau, Maria F Ortu, Erika Salvi, Giovanni Fresu, Lorena Citterio, Daniele Braga, Daniela A Piras, Simona Delli Carpini, Dinesh Velayutham, Marco Simonini, Giuseppe Argiolas, Simona Pozzoli, Chiara Troffa, Valeria Glorioso, Kimmo K Kontula, Timo P Hiltunen, Kati M Donner, Stephen T Turner, Eric Boerwinkle, Arlene B Chapman, Sandosh Padmanabhan, Anna F Dominiczak, Olle Melander, Julie A Johnson, Rhonda M Cooper-Dehoff, Yan Gong, Natalia V Rivera, Gianluigi Condorelli, Bruno Trimarco, Paolo Manunta, Daniele Cusi, Nicola Glorioso, Cristina Barlassina.   

Abstract

BACKGROUND: Thiazide diuretics have been recommended as a first-line antihypertensive treatment, although the choice of 'the right drug in the individual essential hypertensive patient' remains still empirical. Essential hypertension is a complex, polygenic disease derived from the interaction of patient's genetic background with the environment. Pharmacogenomics could be a useful tool to pinpoint gene variants involved in antihypertensive drug response, thus optimizing therapeutic advantages and minimizing side effects. METHODS AND
RESULTS: We looked for variants associated with blood pressure response to hydrochlorothiazide over an 8-week follow-up by means of a genome-wide association analysis in two Italian cohorts of never-treated essential hypertensive patients: 343 samples from Sardinia and 142 from Milan. TET2 and CSMD1 as plausible candidate genes to affect SBP response to hydrochlorothiazide were identified. The specificity of our findings for hydrochlorothiazide was confirmed in an independent cohort of essential hypertensive patients treated with losartan. Our best findings were also tested for replication in four independent hypertensive samples of European Ancestry, such as GENetics of drug RESponsiveness in essential hypertension, Genetic Epidemiology of Responses to Antihypertensives, NORdic DILtiazem intervention, Pharmacogenomics Evaluation of Antihypertensive Responses, and Campania Salute Network-StayOnDiur. We validated a polymorphism in CSMD1 and UGGT2.
CONCLUSION: This exploratory study reports two plausible loci associated with SBP response to hydrochlorothiazide: TET2, an aldosterone-responsive mediator of αENaC gene transcription; and CSMD1, previously described as associated with hypertension in a case-control study.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25695618      PMCID: PMC4484731          DOI: 10.1097/HJH.0000000000000541

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  51 in total

1.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

2.  Both isoforms of human UDP-glucose:glycoprotein glucosyltransferase are enzymatically active.

Authors:  Yoichi Takeda; Akira Seko; Masakazu Hachisu; Shusaku Daikoku; Masayuki Izumi; Akihiko Koizumi; Kohki Fujikawa; Yasuhiro Kajihara; Yukishige Ito
Journal:  Glycobiology       Date:  2014-01-09       Impact factor: 4.313

3.  Inhibition of carbonic anhydrase accounts for the direct vascular effects of hydrochlorothiazide.

Authors:  P Pickkers; R S Garcha; M Schachter; P Smits; A D Hughes
Journal:  Hypertension       Date:  1999-04       Impact factor: 10.190

4.  Feedforward activation of endothelial ENaC by high sodium.

Authors:  Stefanie Korte; Alexandra S Sträter; Verena Drüppel; Hans Oberleithner; Pia Jeggle; Claudia Grossmann; Manfred Fobker; Jerzy-Roch Nofer; Eva Brand; Kristina Kusche-Vihrog
Journal:  FASEB J       Date:  2014-05-27       Impact factor: 5.191

5.  Data quality control in genetic case-control association studies.

Authors:  Carl A Anderson; Fredrik H Pettersson; Geraldine M Clarke; Lon R Cardon; Andrew P Morris; Krina T Zondervan
Journal:  Nat Protoc       Date:  2010-08-26       Impact factor: 13.491

6.  Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.

Authors:  Julie A Johnson; Eric Boerwinkle; Issam Zineh; Arlene B Chapman; Kent Bailey; Rhonda M Cooper-DeHoff; John Gums; R Whit Curry; Yan Gong; Amber L Beitelshees; Gary Schwartz; Stephen T Turner
Journal:  Am Heart J       Date:  2009-03       Impact factor: 4.749

7.  Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase.

Authors:  Erika Salvi; Zoltán Kutalik; Nicola Glorioso; Paola Benaglio; Francesca Frau; Tatiana Kuznetsova; Hisatomi Arima; Clive Hoggart; Jean Tichet; Yury P Nikitin; Costanza Conti; Jitka Seidlerova; Valérie Tikhonoff; Katarzyna Stolarz-Skrzypek; Toby Johnson; Nabila Devos; Laura Zagato; Simonetta Guarrera; Roberta Zaninello; Andrea Calabria; Benedetta Stancanelli; Chiara Troffa; Lutgarde Thijs; Federica Rizzi; Galina Simonova; Sara Lupoli; Giuseppe Argiolas; Daniele Braga; Maria C D'Alessio; Maria F Ortu; Fulvio Ricceri; Maurizio Mercurio; Patrick Descombes; Maurizio Marconi; John Chalmers; Stephen Harrap; Jan Filipovsky; Murielle Bochud; Licia Iacoviello; Justine Ellis; Alice V Stanton; Maris Laan; Sandosh Padmanabhan; Anna F Dominiczak; Nilesh J Samani; Olle Melander; Xavier Jeunemaitre; Paolo Manunta; Amnon Shabo; Paolo Vineis; Francesco P Cappuccio; Mark J Caulfield; Giuseppe Matullo; Carlo Rivolta; Patricia B Munroe; Cristina Barlassina; Jan A Staessen; Jacques S Beckmann; Daniele Cusi
Journal:  Hypertension       Date:  2011-12-19       Impact factor: 10.190

8.  Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension.

Authors:  D Cusi; C Barlassina; T Azzani; G Casari; L Citterio; M Devoto; N Glorioso; C Lanzani; P Manunta; M Righetti; R Rivera; P Stella; C Troffa; L Zagato; G Bianchi
Journal:  Lancet       Date:  1997-05-10       Impact factor: 79.321

9.  Population structure and eigenanalysis.

Authors:  Nick Patterson; Alkes L Price; David Reich
Journal:  PLoS Genet       Date:  2006-12       Impact factor: 5.917

10.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

View more
  16 in total

Review 1.  Pharmacogenomics of hypertension and heart disease.

Authors:  Meghan J Arwood; Larisa H Cavallari; Julio D Duarte
Journal:  Curr Hypertens Rep       Date:  2015-09       Impact factor: 5.369

Review 2.  TET2: A Novel Epigenetic Regulator and Potential Intervention Target for Atherosclerosis.

Authors:  Yami Liu; Wen Peng; Kai Qu; Xiaolong Lin; Zhaolin Zeng; Jiaojiao Chen; Dangheng Wei; Zuo Wang
Journal:  DNA Cell Biol       Date:  2018-04-13       Impact factor: 3.311

Review 3.  Personalized medicine: Genetic risk prediction of drug response.

Authors:  Ge Zhang; Daniel W Nebert
Journal:  Pharmacol Ther       Date:  2017-02-14       Impact factor: 12.310

Review 4.  Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide.

Authors:  Erika Salvi; Zhiying Wang; Federica Rizzi; Yan Gong; Caitrin W McDonough; Sandosh Padmanabhan; Timo P Hiltunen; Chiara Lanzani; Roberta Zaninello; Martina Chittani; Kent R Bailey; Antti-Pekka Sarin; Matteo Barcella; Olle Melander; Arlene B Chapman; Paolo Manunta; Kimmo K Kontula; Nicola Glorioso; Daniele Cusi; Anna F Dominiczak; Julie A Johnson; Cristina Barlassina; Eric Boerwinkle; Rhonda M Cooper-DeHoff; Stephen T Turner
Journal:  Hypertension       Date:  2016-10-31       Impact factor: 10.190

5.  Pharmacoepigenetics of hypertension: genome-wide methylation analysis of responsiveness to four classes of antihypertensive drugs using a double-blind crossover study design.

Authors:  Marja-Liisa Nuotio; Heini Sánez Tähtisalo; Alexandra Lahtinen; Kati Donner; Frej Fyhrquist; Markus Perola; Kimmo K Kontula; Timo P Hiltunen
Journal:  Epigenetics       Date:  2022-02-25       Impact factor: 4.861

Review 6.  Hypertension pharmacogenomics: in search of personalized treatment approaches.

Authors:  Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  Nat Rev Nephrol       Date:  2015-11-23       Impact factor: 28.314

Review 7.  New Developments in the Genetics of Hypertension: What Should Clinicians Know?

Authors:  David S Geller
Journal:  Curr Cardiol Rep       Date:  2015-12       Impact factor: 2.931

8.  Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment.

Authors:  Michael T Eadon; Sri H Kanuri; Arlene B Chapman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2018-01-03

9.  Functional Regression Models for Epistasis Analysis of Multiple Quantitative Traits.

Authors:  Futao Zhang; Dan Xie; Meimei Liang; Momiao Xiong
Journal:  PLoS Genet       Date:  2016-04-22       Impact factor: 5.917

Review 10.  Is There a Role for Genomics in the Management of Hypertension?

Authors:  Jacopo Burrello; Silvia Monticone; Fabrizio Buffolo; Martina Tetti; Franco Veglio; Tracy A Williams; Paolo Mulatero
Journal:  Int J Mol Sci       Date:  2017-05-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.